An impairment charge and weak financial performance led to an over 12 per cent fall in the GSK Pharmaceuticals stock on Tuesday. In addition, the company — as part of its strategic review — is looking at options including sale of its Vemgal facility in Karnataka.
The financial impairment was on account of a global voluntary recall of ranitidine (antacid) products, which include its top brand Zinetac in India. The move was prompted by the detection of a carcinogen in the drug, with the firm indicating it would continue its probe into the potential source of the ...
TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST Rs
Key stories on business-standard.com are available to premium subscribers only.
Already a premium subscriber? LOGIN NOW
First Published: Wed, February 05 2020. 00:13 IST
